# An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

> **NCT05941637** · — · NO_LONGER_AVAILABLE · sponsor: **Lynkcell Europe**

## Conditions studied

- Clear Cell Kidney Cancer
- Kidney Cancer
- Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations

## Interventions

- **DRUG:** Axitinib 5 MG

## Key facts

- **NCT ID:** NCT05941637
- **Lead sponsor:** Lynkcell Europe
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941637, "An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05941637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*